Comparative study of intravenous single doses of palonosetron (PALO) with granisetron hydrochloride as a control in patients receiving highly emetogenic chemotherapy

Trial Profile

Comparative study of intravenous single doses of palonosetron (PALO) with granisetron hydrochloride as a control in patients receiving highly emetogenic chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Palonosetron (Primary) ; Dexamethasone; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms PROTECT
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 11 Oct 2010 Results have been presented at the ESMO (European Society of Medical Oncology) 2010 Congress, according to a Helsinn media release.
    • 08 Oct 2010 Results have been presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
    • 20 Jan 2010 Palonosetron [Aloxi] was approved in Japan based on the results of this trial, according to a Taiho media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top